Todd Meyerrose is a co-founder of Lexent Bio, specializing in liquid biopsy detection for treatment response since its establishment in 2016 until its acquisition by Roche/Foundation Medicine. As a founding partner at BioMed Ventures since 2015, Todd has invested in numerous innovative companies across various sectors, including Osmind, Synapticure, and Rondo Therapeutics. Additionally, Todd serves as a consulting associate professor at Stanford University, co-directing the Biotechnology Business and Finance course. Advisory roles at ixlayer and Genome Medical, alongside multiple investments in emerging biotech firms, further highlight Todd's dedication to advancing healthcare. Todd holds a PhD in Molecular Cell Biology from Washington University School of Medicine and a PhD in Craniofacial Biology and Development from the University of Southern California, along with a BS in Biology from the University of Kentucky.
This person is not in the org chart
This person is not in any teams
This person is not in any offices